Trial Profile
An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen) Who Have Shown Signs of Hemolysis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors CSL Behring
- 11 Dec 2017 New trial record
- 01 Nov 2017 Results published in the Transfusion Journal.